A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...

Shield is the first FDA-approved blood test for primary colorectal ... that would use blood samples to detect colorectal cancers. The device detects a colon cancer secreted protein known as ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial information to make decisions about treatment. But more studies are needed ...

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal ...

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.